Eosinophilic Fasciitis in a 78-Year-Old Man Following Pembrolizumab Treatment for Bladder Cancer

28 September 2025 : Case report USA

Unusual or unexpected effect of treatment, Unexpected drug reaction, Rare disease

Ibiyemi Oke^{BCDEF 1*}, Aleksander Lenert^{CDF 1}, Brian L. Swick^{BD 2}, Petar Lenert^{CDEF 1}

DOI: 10.12659/AJCR.948323

Am J Case Rep 2025; 26:e948323

Authors information Article notes Copyright and License information

Introduction Case Report Discussion Conclusions References

Related articles Order reprints Share article Share by email

View HTML version

Table 1 Laboratory results.

Parameter	Value	Reference range	Unit
IL-5	4.9	≤2.1	pg/ml
IL-6	8.4	≤2.0	pg/ml
IL-10	17.3	≤2.8	pg/ml
Soluble IL-2R	2358.2	175.3–858.2	pg/ml
White blood cells	14,000	3,700–10,500	/mm
Eosinophils	2,323	40–390	/mm
Hemoglobin	12.9	13.2–17.7	/mm
Albumin	2.7	3.4–4.8	g/dl
TSH	51.20	0.27–4.20	mIU/ml
ESR	28	0–15	mm/hr
C-reactive protein	3.2	≤0.5	mg/dl

Back to the Article